CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL-SOLUBLE	STRENGTH	*USP40–NF35*	7258	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMINS TABLETS							*Supplement to USP41–NF36*	*Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								retained as specified in the directions for *Sample solution* to: retained as specified in the directions for *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USP40–NF35*	7336	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1/Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Vitamin A, Method 1/Sample solution*: Change Dilute a volume of this solution to: *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Dilute a volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*:Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Vitamin E, Method 1*/*Sample solution*:Change prepared as directed for the *Sample solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prepared as directed for the *Sample stock solution* AND Line 2 of *P hyt onadio ne*:Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE PHOSPHATE CAPSULES	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8201	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>/ Analysis*:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								amount of acetaminophen AND In the Calculate statement of *Uniformity of Dosage Units <905>/ Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg, of the labeled amount of codeine phosphate to: Calculate the quantity, in mg, of codeine phosphate
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	OTHER COMPONENTS/*Content of Potassium*	*Revision Bulletin (Official April 01, 2017)*	Online	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Sample solution*: Change Transfer 3.0 mL of the clear filtrate, reserved

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Assay*, to a 100-mL volumetric flask. to: *Sample stock solution*: Dilute the clear filtrate, reserved from the *Assay*, with water to obtain a solution containing about 160 µg/mL of potassium citrate monohydrate. *Sample solution*: Transfer 3.0 mL of the *Sample stock solution* to a 100-mL volumetric flask.
ONDANSETRON INJECTION	*USP Reference standards <11>*	*USP40–NF35*	5443	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
ROCURONIUM BROMIDE	IMPURITIES/*Limit of 2-Propanol/Analysis*	*USP40–NF35*	6066	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of the variable definition list: Change r_U = peak response of any impurity from the *Sample solution* r_S = peak response of rocuronium bromide from the *Dilute standard solution* to: *r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_U = peak response of 2-propanol from the *Sample solution* r_S = peak response of 2-propanol from the *Dilute standard solution*
OIL- AND WATER-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7290	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1/Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for the *Sample stock solution* AND Line 2 of *Phytonadione/Sample solution*:Change in the directions for the *Sample solution* to: in the directions for the *Sample stock solution*
MONOSACCHARIDE ANALYSIS	PROCEDURES /*Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids*	*First Supplement to USP40–NF35*	8059	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 6 of *Analysis*: Change (1 M = 1nmol/mL). to: (1 µM = 1nmol/mL).
LEVOTHYROXINE SODIUM TABLETS	IM PURITIES/*Limit of Liothyronine Sodium*	*First Supplement to USP40–NF35*	8328	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4 of *Analysis*: Change Calculate the percentage of levothyroxine sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{15}H_{11}I_3NNaO_4$) to: Calculate the percentage of liothyronine sodium ($C_{15}H_{11}I_3NNaO_4$)
DOXAZOSIN MESYLATE	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP40–NF35*	3874	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Resolution*: Change NLT 4 to: NLT 2
PERPHENAZINE	IMPURITIES/*Organic Impurities*/*Chromatographic system*	*USP40–NF35*	5649	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Column*: Change 4.6-mm to: 4.0-mm
OIL-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USP40–NF35*	7265	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 21 of *Sample solution*: Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carotene*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7375	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D),*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Method 1/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Vitamin E, Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8202	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>*/*Analysis*:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the second Calculate statement in *Uniformity of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TIMOLOL MALEATE	MULTIPLE SECTIONS	*Second Supplement to USP40–NF35*	Online	28-Jul-2017	1-Aug-2017	*USP41–NF36*	*USP41–NF36*	*Dosage Units <905>/ Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg/mL, of the labeled amount of codeine phosphate to: Calculate the quantity, in mg, of codeine phosphate The version of the Timolol Maleate monograph which appeared in the *Second Supplement to USP 40–NF 35* did not include the revisions approved in the version appearing in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								First Supplement to USP 40–NF 35. The version appearing in the *First Supplement* should be used. The file as it should have appeared in the *Second Supplement* is attached to the compendial notice found at http://www.uspnf.com/notices/second-supplement-usp-40-nf-35-online-timolol-maleate.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USP40–NF35*	5444	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7248	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1/Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for the *Sample stock solution* AND Line 1 of *Phytonadione/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP40–NF35*	7318	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1/Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change retained as specified in the directions for the *Sample solution* to: retained as specified in the directions for the *Sample stock solution*
G49	CHROMATOGRAPHIC CO	*First Supplement to USP40–NF35*	8127	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Add G49—Dimethylpolysiloxane with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	LUMNS/*Packings*							chiral building block containing D- or L-valine as chiral agent (for amino acids).
NEOTAME	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	8485	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Neotame Related Compound A RS: Change *N*-[3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine. to: *N*-[*N*-(3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine.
ONDANSETRON HYDROCHLORIDE	*USP Reference standards <11>*	*USP40–NF35*	5441	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
PROPANTHELINE BROMIDE	IMPURITIES/*Organic Impurities/ Chromatographic system*	*USP40–NF35*	5882	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Run time*: Change NMT to: NLT
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7280	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 15 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*: Change prepared as directed for the *Sample solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carotene*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SHELLAC	IM PURITIES/*Limit of Chloride*	*USP40–NF35*	7869	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Control solution*: Change 0.1 M hydrochloric acid VS, to: 0.01 M hydrochloric acid VS,
PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP40–NF35*	5720	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of *Standard solution*: Change USP Metformin Hydrochloride RS in *Diluent A* to: USP Metformin Hydrochloride RS from the *Metformin standard stock solution* in *Diluent A*
METHIONINE	IM PURITIES/*Related Compounds*	*First Supplement to USP40–NF35*	8337	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Row 5 of Column 3 of *Table 2*: Change 0.1 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NUCLEIC ACID-BASED TECHNIQUES—GENERAL	*Appendix 1: Regulations and Standards*	*USP40–NF35*	1471	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	1.0 Line 1 of bullet 1: Change "Review Criteria for Nucleic Acid Amplification-Based In Vitro Diagnostic Devices for Direct Detection of Infectious Microorganisms" (1993) to: "Nucleic Acid Based In Vitro Diagnostic Devices for Detection of Microbial Pathogens" (2005)
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP40–NF35*	5251	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of *Sample solution*: Change 45-µm pore size. to: 0.45-µm pore size.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EVENING PRIMROSE OIL CAPSULES	STRENGTH/*Analysis*	*USP40–NF35*	6952	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	In the first variable definition list: Change m_S = weight of USP Methyl Ester RS in the *Standard solution* (mg) to: m_S = weight of the relevant USP Methyl Ester RS in the *Standard solution* (mg)
TIMOLOL MALEATE	IMPURITIES/ *Enantiomeric Purity*	*First Supplement to USP40–NF35*	8416	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 6 of *Chromatographic system*: Delete *Autosampler temperature*: 4°
OLIGOSACCHARIDE ANALYSIS	SEPARATION AND IDENTIFICATION OF OLIGOSACCHARIDES	*USP40–NF35*	273	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Normal Phase Chromatography/HILIC/ Ammonium formate buffer*: Change Add *1.4 M ammonia*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to *1.4 M formic acid solution*. to: Add *1.4 M ammonia solution* to *1.4 M formic acid solution* until a pH of 4.4 is obtained.
GLUCONOLACTONE	ASSAY/ *Procedure*	*USP40–NF35*	4412	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 5 of *Analysis*: Change Each mL of *Back-titrant* to: Each milliliter of *Titrant*
POLYETHYLENE GLYCOL 3350	SPECIFIC TESTS/ *Apparent Weight-Average Molecular Weight and Polydispersity*	*USP40–NF35*	5745	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Standard solution*: Change *Standard solution*: 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1000,2000, 3000, 4000, and 6000 g/mol (Da) in *Mobilephase*. Pass a portion of the solution to: *Standard solutions*: Prepare 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in *Mobilephase* separately in five individual flasks. Pass a portion of each solution AND Line 1 of *Analysis/Samples*: Change *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution and *Sample solution* to: *Standard solutions* and *Sample solution* AND Line 3 of *Analysis*: Change Separately inject equal volumes of the *Standard solution* to: Separately inject equal volumes of the *Standard solutions*
METHYLDOPA	ASSAY/ *Procedure/ Chromatographic system*	*First Supplement to USP40–NF35*	8339	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Injection volume*: Change 1 mL to: 20 µL
ACETYLCYSTEINE SOLUTION	ASSAY/ *Procedure*	*USP40–NF35*	2586	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHENYTOIN ORAL SUSPENSION	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5690	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Change *Standard stock solution* to: *Sample stock solution* Line 1 of *Sample solution*: Change 1 mg/mL of Oral Suspension in *Diluent* to: Nominally 1 mg/mL of phenytoin prepared as follows. Weigh and transfer a suitable volume of Oral Suspension to an appropriate volumetric flask. Add methanol to about 20% of the final flask volume and dissolve. Dilute with *Diluent* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume. Dissolve with the aid of sonication, if necessary.
SUCROSE	SPECIFIC TESTS/*Color Value/Analysis*	*USP40–NF35*	7938	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 6 of the variable definition list: Change The absolute difference between two results is NMT 3. to: *Suitability requirements Repeatability*: The absolute difference between two results is NMT 3.
DOCETAXEL	IM PUR ITIES/*Organic Impurities, Procedure 1*	*Revision Bulletin (Official August 01, 2016)*	Online	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Footnote c of *Table 2*: Change (2a*R*,4*R*,4a*S*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								12b-Dodecahydro-4, 9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-5,6-dione 12b-acetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-formyl-3-phenylisoserine. to: (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)?12b?Acetoxy?9?(((2*R*,3*S*)?3?formamido?2?hydroxy?3?phenylpropanoyl)oxy)?4,6,11?trihydroxy?4a,8,13,13?tetramethyl?5?oxo?2a,3,4,4a,5,6,9,10,11,12,1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2a,12b?dodeca hydro?1*H* ?7,11?methano cyclodeca[3,4]b enzo[1,2?*b*]oxet-12?yl benzoate. AND Footnote d of *Table 2*: Change (2a*R*,4*R*,4a*S* ,6*R*,9*S*,11*S* ,12*S*,12a*R* ,12b*S*)-6-{[(2,2-Dichlo roethoxy)carbon yl]oxy}-1,2a,3,4, 4a,6,9,10,11,12, 12a,12b-dodeca hydro-4,9,11,12 ,12b-pentahydr oxy-4a,8,13,13-t etramethyl-7,11 -met hano-5*H* -cyclodeca[3,4] benz[1 ,2-*b*)oxet-5-one 12b-acetate,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								12-benzoate, 9-ester with (2*R*,3*S*)-*N*-tert-butoxycarbonyl-e-phenylisoserine. to: (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)?6?{[(2,2?Dichloroethoxy)carbonyl]oxy}?1,2a,3,4,4a,6,9,10,11,12,12a,12b?dodecahydro?4,9,11,12,12b?pentahydroxy?4a,8,13,13?tetramethyl?7,11?meth ano?5*H* ?cyclodeca[3,4]benz[1,2?*b*]oxet?5?one 12b?acetate, 12?benzoate,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9?ester with (2*R*,3*S*)?*N*?tert-butoxycarbonyl?3?phenylisoserine.
TOPICAL AEROSOLS	DELIVERED-DOSE UNIFORMITY	*USP40–NF35*	499	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 2: Change proceed as directed in the test for *Delivered Dose Uniformity* in *Metered-Dose Inhalers and Dry Powder Inhalers*, as described in <601>, to: proceed as directed in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests <601>*, *A. Delivered-Dose Uniformity*/*A.2 Inhalation*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Aerosols and Inhalation Sprays and *A.4 Inhalation Powders*, AND Line 4: Delete Unless otherwise stated in the individual monograph, apply the acceptance criteria for *Metered-Dose Inhalers and Dry Powder Inhalers* as described in <601>.
IOHEXOL	IM PURITIES/*Limit of Free Iodide*/*Analysis*	*USP40–NF35*	4649	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of variable definition list: Change 0.1269 mg/mEq to: 126.9 mg/mEq
SCAFFOLD BOVINE DERMIS	SPECIFIC TESTS	*USP40–NF35*	6113	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 5 of *Carbohydrate Content*/

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acceptance criteria: Change *Moisture Content* to: *Loss on Drying* AND Line 3 of *Suture Retention Force*/*Analysis*: Change 40 to: 4-0
TIMOLOL MALEATE	IDENTIFICATION/*B.*	*First Supplement to USP40–NF35*	8416	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1: Change major peak of the *Sample solution* corresponds to that of the *Standard solution*, to: timolol peak of the *Sample solution* corresponds to that of the *System suitability solution*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLOW CYTOMETRIC ENUMERATION OF CD34+ CELLS	SAMPLE PREPARATION/*Table 1. Dot Plot Descriptions and Gating Instructions*	*USP40–NF35*	216	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Column 4 for Step 6: Add • For counting bead enumeration, proceed to either Step 7 or Step 8 according to the recommendations of the bead manufacturer.
CONSTRUCT HUMAN FIBROBLASTS IN BILAYER SYNTHETIC SCAFFOLD	SPECIFIC TESTS/*Metabolic Activity Assessment*	*USP40–NF35*	3561	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 2 of *L-Glutamine solution*: Change 29.2 g to: 2.92 g
MYCOPHENOLATE MOFETIL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4957	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Line 5 of USP Mycophenolate Mofetil Related Compound A RS: Change $C_{23}H_{31}NO_7$ to: $C_{22}H_{29}NO_7$
VINORELBINE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP39–NF34*	6371	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Line 2 of USP Vinorelbine Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 4-*O* -Deacetylvinorelbine. to: 4-*O* -Deacetylvinorelbine tartrate.
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8101	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Change *Buffer*, *Mobile phase*, *Diluent*, and *Sample solution*: Prepare as directed in the *Assay*. to: *Buffer*, *Mobile phase*, and *Diluent*: Prepare as directed in the *Assay*. AND Add *Sample solution*: Use the *Sample stock solution* as directed in the *Assay*.
SPACERS	1. INTRODUCT	*USP40–NF35*	1988	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Bottom right

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AND VALVED HOLDING CHAMBERS USED WITH INHALATION AEROSOLS—CHARACTERIZATION TESTS	ION/*1.5 Definitions of Key Terms Relating to This Chapter*							corner of *Figure 1*:Change VHC mouthpiece to: Spacer mouthpiece
GRANISETRON HYDROCHLORIDE TABLETS	*USP Reference standards <11>*	*First Supplement to USP40–NF35*	Online	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of USP Granisetron Related Compound C RS: Change carboxamide. to: carboxamide hydrochloride.
DOBUTAMINE INJECTION	IDENTIFICATION/*A.*	*USP39–NF34*	3561	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Sample solution*: Change 10 mg/mL of dobutamine hydrochloride in methanol, clarified by centrifugation to: Use the neat Injection.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- …
- Next page Next ›
- Last page Last »